F	FC)F	R	N	4	
l	-				1.0	

Check this box if no					
longer subject to					
Section 16. Form 4 or					
Form 5 obligations					
may continue. See					
Instruction 1(b).					

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting Person + White Barbara	2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) C/O CORBUS PHARMACEUTICAL INC, 100 RIVER RIDGE DRIVE	(Middle) S HOLDINGS,	3. Date of Earliest Transaction (Month/Day/Year) 10/06/2016					X Officer (give title below) Other (specify below) Chief Medical Officer			
(Street) NORWOOD, MA 02062		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acqu					Acqu	ired, Disposed of, or Beneficially Own	ed	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year	Execution Date, if any	(Instr. 8)	ion	4. Securi (A) or Di (Instr. 3,	isposed o		Owned Following Reported Transaction(s)	6. Ownership Form:	Beneficial
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
	•	-	•					•	•	· · · · · ·

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly	у.
	2

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

_	(e.g., puts, calls, warrants, options, convertible securities)														
	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	ion)		(A) ed	6. Date Exercisable and Expiration Date (Month/Day/Year)		ar) 7. Title and Amount of Underlying Securities		Derivative Security (Instr. 5)	Security Securities (Instr. 5) Beneficially		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option(right to buy)	\$ 8.71	10/06/2016		А		150,000		<u>(1)</u>	10/06/2026	Common Stock	150,000	\$ 0	150,000	D	

Reporting Owners

Densetter Ormen News (Address		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
White Barbara C/O CORBUS PHARMACEUTICALS HOLDINGS, I 100 RIVER RIDGE DRIVE NORWOOD, MA 02062	NC		Chief Medical Officer					

Signatures

/s/ Barbara White	10/07/2016
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on October 6, 2017, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 6, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.